Articles From: Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology" to NeuroMetrix to Present at Biotech Showcase 2015


Study Concludes NSI-566 Cells Survived for up to 2.5 Years After Transplantation GERMANTOWN, Md.
Sign-up for Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology" investment picks
Depression Biomarker Analysis Shows NSI-189 is Rapidly and Persistently Efficacious GERMANTOWN, Md.
Sign-up for Neuralstem NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit investment picks
2014/11/7
GERMANTOWN, Md.
Sign-up for Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update investment picks
2015/1/6
GERMANTOWN, Md.
Sign-up for Neuralstem To Present At Biotech Showcase 2015 investment picks
Conference Call and Webcast Scheduled for Monday, November 3, 2014 SAN DIEGO , Oct.
Sign-up for Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2014 Financial Results investment picks
Phase I/II Clinical Trial of CRF Antagonist in Adolescent Females with Classic Congenital Adrenal Hyperplasia Initial Pilot Clinical Study Demonstrated Profound Impact on Key Biomarkers SAN DIEGO , Dec.
Sign-up for Neurocrine Biosciences Announces Expansion of its Clinical Pipeline investment picks
NBI-98854 Phase III Program Underway for Tardive Dyskinesia Tourette Syndrome Phase IB Study Initiated FDA Grants Breakthrough Therapy Designation for Tardive Dyskinesia SAN DIEGO , Nov.
Sign-up for Neurocrine Biosciences Reports Third Quarter 2014 Results investment picks
Live Audio Webcast will be on December 10, 2014 SAN DIEGO , Dec.
Sign-up for Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference investment picks
Live Audio Webcast will be on January 15, 2015 SAN DIEGO , Jan.
Sign-up for Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
Live Audio Webcast will be on November 19, 2014 SAN DIEGO , Nov.
Sign-up for Neurocrine Biosciences to Present at the Jefferies 2014 Global Healthcare Conference investment picks
Live Audio Webcast will be on November 6, 2014 SAN DIEGO , Nov.
Sign-up for Neurocrine Biosciences to Present at the Nomura Biotechnology Conference investment picks
Live Audio Webcasts will be on December 2nd and 3rd, 2014 SAN DIEGO , Nov.
Sign-up for Neurocrine to Present at the 2014 Deutsche Bank BioFEST and the 26th Annual Piper Jaffray Healthcare Conference investment picks
REHOVOT, Israel, Dec.
Sign-up for NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update investment picks
REHOVOT, Israel, Dec.
Sign-up for NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014 investment picks
NeuroDerm Ltd.
Sign-up for NeuroDerm shares surge 19.6% as Parkinson's treatment shows promise investment picks
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent application covering unique aspects of the Company’s wearable pain relief technology.
Sign-up for NeuroMetrix Expands Intellectual Property for Wearable Pain Relief Technology investment picks
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that industry insiders got their first look at Quell during day 1 of this year’s International Consumer Electronics Show (CES). Quell utilizes NeuroMetrix’s proprietary non-invasive neurostimulation technology to provide relief from chronic pain, particularly nerve pain such as due to diabetes and lower back problems.
Sign-up for NeuroMetrix Launches Quell™ Wearable Pain Relief Technology at 2015 International Consumer Electronics Show to Strong Initial Interest investment picks
NeuroMetrix, Inc. (Nasdaq:NURO) reported that its President and Chief Executive Officer, Shai N.
Sign-up for NeuroMetrix Presents Business Overview at Biotech Showcase 2015 investment picks
NeuroMetrix, Inc. (Nasdaq: NURO) reported today that Quell has been featured in several forums during this year’s International Consumer Electronics Show (CES). Among the highlights: Quell utilizes NeuroMetrix's proprietary non-invasive neurostimulation technology to provide relief from chronic pain, such as due to diabetes, sciatica, fibromyalgia, and degenerative knee conditions.
Sign-up for NeuroMetrix Quell™ Wearable Pain Relief Technology Attracts Broad Attention at International Consumer Electronics Show investment picks
NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), today reported business highlights for the quarter ended September 30, 2014.
Sign-up for NeuroMetrix Reports Third Quarter 2014 Financial Results and Business Highlights investment picks
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it will join an exclusive number of companies to participate in CES Unveiled, the official press event of the International Consumer Electronics Show in Las Vegas in January 2015.
Sign-up for NeuroMetrix Selected to Showcase Quell™ Wearable Pain Relief Technology at 2015 CES Unveiled investment picks
NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N.
Sign-up for NeuroMetrix to Participate in the Benchmark Micro Cap Discovery Conference investment picks
2015/1/6
NeuroMetrix, Inc. announced today that Shai N.
Sign-up for NeuroMetrix to Present at Biotech Showcase 2015 investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Neuralstem Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology" to NeuroMetrix to Present at Biotech Showcase 2015
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent